Streetbeat News

SPRY

ARS Pharmaceuticals, Inc.

Industry

Biotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Open

10.53

Mkt cap

Volume

302K

High

10.64

P/E Ratio

-21.00

52-wk high

18.51

Low

10.28

Div yield

N/A

52-wk low

7.55

ARS Pharmaceuticals will present data on their epinephrine nasal spray, neffy, at the 2025 AAAAI Annual Meeting. Studies show neffy is effective and safe for managing anaphylaxis, offering a needle-free alternative to traditional treatments.

Portfolio Pulse from

February 18, 2025 | 1:15 pm

ARS Pharmaceuticals has launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. Early sales have exceeded expectations, indicating its potential as a blockbuster product. Neffy targets multiple segments within severe allergic reactions and may become an OTC medication, representing a multibillion-dollar total addressable market.

Portfolio Pulse from

February 06, 2025 | 6:15 am

ARS Pharmaceuticals has announced that its product, neffy® (Epinephrine Nasal Spray), is now available on Express Scripts Commercial National Formularies as of November 22, 2024. This inclusion expands access for patients and caregivers managing Type 1 Allergic Reactions.

Portfolio Pulse from

December 19, 2024 | 10:45 pm

ARS Pharmaceuticals has announced that its licensing partners have filed for approval of neffy, an epinephrine nasal spray, in China, Japan, and Australia. This marks a significant step in expanding the product's availability in the Asia Pacific region.

Portfolio Pulse from

December 12, 2024 | 7:45 pm

ARS Pharmaceuticals is launching the neffyinSchools program to provide free needle-free epinephrine nasal spray to eligible K-12 schools in the U.S. This initiative aims to enhance emergency treatment for allergic reactions, including anaphylaxis.

Portfolio Pulse from

December 04, 2024 | 1:15 pm

ARS Pharmaceuticals, Inc. (SPRY) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included company executives and analysts from major financial firms.

Portfolio Pulse from

November 13, 2024 | 6:00 pm

ARS Pharmaceuticals, Inc. (SPRY) reported a Q3 loss of $0.20 per share, missing the Zacks Consensus Estimate of a $0.18 loss. This is a larger loss compared to $0.16 per share a year ago.

Portfolio Pulse from

November 13, 2024 | 2:00 pm

ARS Pharmaceuticals has launched neffy, an epinephrine nasal spray, in the US and received priority review for a supplemental NDA. They have an exclusive license agreement with ALK-Abelló for commercialization in Europe and Canada, with a potential deal value of $465 million. The company is well-capitalized with $349.6 million in cash.

Portfolio Pulse from

November 13, 2024 | 11:45 am

Wall Street analysts have set an average price target for ARS Pharmaceuticals, Inc. (SPRY) that suggests a potential upside of 67.6%. This optimistic outlook is supported by positive trends in earnings estimate revisions.

Portfolio Pulse from

November 06, 2024 | 4:00 pm

ARS Pharmaceuticals is presenting seven abstracts on intranasal epinephrine at the 2024 ACAAI Annual Scientific Meeting, covering topics like cardiovascular safety and real-world data in pediatric patients.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.